Easom Eric
SEC insider (Form 3/4/5 filer). CIK 0001914503. Chief Executive Officer at AN2 Therapeutics, Inc. (ANTX). 10 reported Form 4/5 transactions since Sep 2024; latest on Mar 19, 2026. Located in MENLO PARK, CA.
Companies Easom Eric has filed insider reports for
- AN2 Therapeutics, Inc. (ANTX): Director, Officer, Chief Executive Officer
Easom Eric
CIK: 0001914503
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AN2 Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
267.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
250K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
225K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
DispositionDirectStock Option (right to buy)
225K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
267.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirectStock Option (right to buy)
250K shares- - Feb 20, 2026ANTX
AN2 Therapeutics, Inc.
AwardDirect112.3K shares- - Jun 2, 2025ANTX
AN2 Therapeutics, Inc.
PurchaseDirect10K shares at avg. $1.07$11K - Feb 26, 2025ANTX
AN2 Therapeutics, Inc.
AwardDirect145.3K shares- - Nov 18, 2024ANTX
AN2 Therapeutics, Inc.
PurchaseIndirect50K shares at avg. $1.00$50K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 267,650 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 249,999 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 225,000 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition Stock Option (right to buy) | 225,000 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 267,650 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award Stock Option (right to buy) | 249,999 | - | - | Direct |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | Award | 112,250 | - | $0 | Direct |
| Jun 2, 2025 | ANTX AN2 Therapeutics, Inc. | Purchase | 10,000 | $1.07 | $10,665 | Direct |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | Award | 145,250 | - | - | Direct |
| Nov 18, 2024 | ANTX AN2 Therapeutics, Inc. | Purchase | 50,000 | $1.00 | $49,970 | Indirect |
1-10 of 10 transactions